Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. This burden will increase further as the population ages and the degree of polypharmacy increases. Knowledge about DDIs comes from many sources, with rigorous population-based studies of clinical outcomes providing the most clinically useful information. Because very few population DDI studies have been performed, there is profound disagreement among the DDI compendia about which drug pairs cause clinically important DDIs. Further, uncertainty about which potential DDIs are clinically important has hampered efforts to mitigate the effects of DDIs, such as computerized decision support. Population studies of the clinical effects of DDIs are therefore badly needed, and should be integrated with research on the biological basis of DDIs. In this renewal application, we propose to extend our approach to population DDI studies in two important and innovative ways: 1) by actively and explicitly incorporating mechanistic considerations;and 2) by implementing a sequential approach of initially identifying and quantifying risk, then, where warranted based on this step, characterizing important DDIs further, with the goal of providing the basis for future efforts to mitigate risk. Based on an extensive and structured consultative process to identify research foci, we propose to conduct a series of population DDI studies using a large 5-state Medicaid/Medicare dataset. These studies will examine hypothesized interactions involving lipid lowering drugs, anti-clotting drugs, and oral anti-diabetic drugs, three drug classes with enormous relevance for older adults, and with high potential for causing clinically important DDIs. Thus, we will study potential DDIs of great clinical and public health importance, especially to older adults, and in the process develop data that will help elucidate the mechanisms of these potential DDIs.

Public Health Relevance

Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. However, little is known about the clinical importance of most potential DDIs. We will conduct large population studies of the clinical importance of potential DDIs affecting lipid lowering, anti-clotting, and anti-diabetic therapies, addressing potential DDIs of great clinical and public health importance.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Neurological, Aging and Musculoskeletal Epidemiology (NAME)
Program Officer
Salive, Marcel
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Biostatistics & Other Math Sci
Schools of Medicine
United States
Zip Code
Schelleman, H; Han, X; Brensinger, C M et al. (2014) Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol 78:639-48
Ogdie, Alexis; Haynes, Kevin; Troxel, Andrea B et al. (2014) Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis 73:149-53
Leonard, Charles E; Razzaghi, Hanieh; Freeman, Cristin P et al. (2014) Empiric potassium supplementation and increased survival in users of loop diuretics. PLoS One 9:e102279
Ogdie, Alexis; Alehashemi, Sara; Love, Thorvardur Jon et al. (2014) Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf 23:918-22
Leonard, Charles E; Freeman, Cristin P; Newcomb, Craig W et al. (2013) Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States. J Clin Exp Cardiolog Suppl 10:1-9
Lerman, Melissa A; Burnham, Jon M; Chang, Peter Y et al. (2013) Response of pediatric uveitis to tumor necrosis factor-* inhibitors. J Rheumatol 40:1394-403
Hennessy, S; Flockhart, D A (2012) The need for translational research on drug-drug interactions. Clin Pharmacol Ther 91:771-3
Hennessy, S (2011) When should we believe nonrandomized studies of comparative effectiveness? Clin Pharmacol Ther 90:764-6
Schelleman, Hedi; Brensinger, Colleen M; Bilker, Warren B et al. (2011) Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 6:e21447
Wade, Kelly C; Ellenberg, Jonas H; Grosser, Tilo et al. (2011) Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women. J Cardiovasc Pharmacol 57:194-200

Showing the most recent 10 out of 13 publications